Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up - Time to Buy?

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $19.57, but opened at $20.23. Celldex Therapeutics shares last traded at $20.28, with a volume of 48,289 shares.

Analyst Ratings Changes

CLDX has been the topic of a number of analyst reports. Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a research note on Monday. They set a "buy" rating and a $64.00 price objective on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Friday, February 28th. Morgan Stanley assumed coverage on shares of Celldex Therapeutics in a report on Thursday, March 20th. They set an "overweight" rating and a $46.00 price objective on the stock. Finally, UBS Group initiated coverage on Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 price objective on the stock. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $55.30.

Celldex Therapeutics Trading Down 0.2 %

The firm's fifty day simple moving average is $19.10 and its two-hundred day simple moving average is $23.27. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -8.04 and a beta of 1.59.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.02. The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. As a group, analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. boosted its position in shares of Celldex Therapeutics by 2.1% during the fourth quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock worth $1,064,000 after buying an additional 871 shares during the period. EverSource Wealth Advisors LLC grew its position in Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 878 shares in the last quarter. Values First Advisors Inc. increased its stake in Celldex Therapeutics by 3.2% during the first quarter. Values First Advisors Inc. now owns 29,933 shares of the biopharmaceutical company's stock worth $550,000 after purchasing an additional 924 shares during the period. Swiss National Bank lifted its position in shares of Celldex Therapeutics by 1.2% during the fourth quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company's stock worth $2,964,000 after purchasing an additional 1,400 shares in the last quarter. Finally, KBC Group NV increased its stake in Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 1,647 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.